197 related articles for article (PubMed ID: 37697248)
21. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
[TBL] [Abstract][Full Text] [Related]
22. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
24. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
25. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
26. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
[No Abstract] [Full Text] [Related]
27. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
[TBL] [Abstract][Full Text] [Related]
28. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
29. Contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2017)- a valuable tool for the noninvasive diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
Ghiuchici AM; Dănilă M; Popescu A; Șirli R; Moga T; Topan M; Bende F; Sporea I
Med Ultrason; 2021 Nov; 23(4):383-389. PubMed ID: 33793696
[TBL] [Abstract][Full Text] [Related]
30. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
31. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.
Huang Z; Zhou PP; Li SS; Li K
Cancer Imaging; 2023 Mar; 23(1):24. PubMed ID: 36879352
[TBL] [Abstract][Full Text] [Related]
32. Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.
Pan JM; Chen W; Zheng YL; Cheng MQ; Zeng D; Huang H; Huang Y; Xie XY; Lu MD; Kuang M; Hu HT; Chen LD; Wang W
Br J Radiol; 2021 Oct; 94(1126):20201359. PubMed ID: 34545763
[TBL] [Abstract][Full Text] [Related]
33. Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017.
Zeng D; Xu M; Liang JY; Cheng MQ; Huang H; Pan JM; Huang Y; Tong WJ; Xie XY; Lu MD; Kuang M; Chen LD; Hu HT; Wang W
Radiol Med; 2022 Jan; 127(1):1-10. PubMed ID: 34665430
[TBL] [Abstract][Full Text] [Related]
34. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.
Guo D; Wan W; Bai X; Wen R; Peng J; Lin P; Liao W; Huang W; Liu D; Peng Y; Kang T; Yang H; He Y
Abdom Radiol (NY); 2024 May; 49(5):1432-1443. PubMed ID: 38584190
[TBL] [Abstract][Full Text] [Related]
35. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
Makoyeva A; Kim TK; Jang HJ; Medellin A; Wilson SR
Radiol Imaging Cancer; 2020 Mar; 2(2):e190014. PubMed ID: 33778701
[TBL] [Abstract][Full Text] [Related]
36. The comparison of contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI LI-RADS for nodules ≤2 cm in patients at high risk for HCC: a prospective study.
Qin Z; Zhou Y; Zhang X; Ding J; Zhou H; Wang Y; Zhao L; Chen C; Jing X
Front Oncol; 2024; 14():1345981. PubMed ID: 38774417
[TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
Huang Z; Zhou P; Li S; Li K
Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
40. Feeding artery: a valuable feature for differentiation of regenerative nodule, dysplastic nodules and small hepatocellular carcinoma in CEUS LI-RADS.
Wu J; Zhao Q; Wang Y; Xiao F; Cai W; Liu S; Du Z; Yu X; Liu F; Yu J; Liang P
Eur Radiol; 2024 Feb; 34(2):745-754. PubMed ID: 37589899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
